Caribou Biosciences, Inc.

NasdaqGS:CRBU Voorraadrapport

Marktkapitalisatie: US$177.5m

Caribou Biosciences Beheer

Beheer criteriumcontroles 2/4

De CEO Caribou Biosciences is Rachel Haurwitz, benoemd in Oct2011, heeft een ambtstermijn van 13.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.12M, bestaande uit 20% salaris en 80% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.044% van de aandelen van het bedrijf, ter waarde $ 78.39K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 3.5 jaar.

Belangrijke informatie

Rachel Haurwitz

Algemeen directeur

US$3.1m

Totale compensatie

Percentage CEO-salaris20.0%
Dienstverband CEO13.1yrs
Eigendom CEO0.04%
Management gemiddelde ambtstermijn3yrs
Gemiddelde ambtstermijn bestuur3.5yrs

Recente managementupdates

Recent updates

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Nov 05
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Sep 30

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Sep 06
Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Jul 26
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05
Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17
More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10
Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24
Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16
Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13
Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Caribou Biosciences: Selling Close To Cash Balance

Apr 26

We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate

Oct 26
We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate

Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold

Oct 12

Analyse CEO-vergoeding

Hoe is Rachel Haurwitz's beloning veranderd ten opzichte van Caribou Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$148m

Jun 30 2024n/an/a

-US$123m

Mar 31 2024n/an/a

-US$115m

Dec 31 2023US$3mUS$623k

-US$102m

Sep 30 2023n/an/a

-US$95m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$108m

Dec 31 2022US$833kUS$513k

-US$99m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$6mUS$527k

-US$67m

Sep 30 2021n/an/a

-US$63m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$664kUS$450k

-US$34m

Dec 31 2019US$540kUS$425k

-US$23m

Compensatie versus markt: De totale vergoeding ($USD 3.12M ) Rachel } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).

Compensatie versus inkomsten: De vergoeding van Rachel is gestegen terwijl het bedrijf verliesgevend is.


CEO

Rachel Haurwitz (38 yo)

13.1yrs

Tenure

US$3,116,547

Compensatie

Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She served as independent Director at Seer, Inc. since December 21, 2023 u...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Rachel Haurwitz
Co-Founder13.1yrsUS$3.12m0.044%
$ 78.4k
Steven Kanner
Chief Scientific Officer7.4yrsUS$1.22m0.39%
$ 693.9k
Barbara McClung
Chief Legal Officer & Corporate Secretary9.6yrsUS$1.22m0.42%
$ 738.1k
Ryan Fischesser
Interim Principal Accounting Officerless than a yeargeen gegevens0.078%
$ 138.1k
Daniel Poon
Vice President of Operations & Information Technology2.4yrsgeen gegevensgeen gegevens
Timothy Kelly
Chief Technology Officerless than a yeargeen gegevensgeen gegevens
Amy Figueroa
Vice President of Investor Relations & Corporate Communications3yrsgeen gegevensgeen gegevens
Reigin Zawadzki
Chief People Officer1.2yrsgeen gegevensgeen gegevens
Ruhi Khan
Chief Business Officer3yrsUS$1.04m0%
$ 0

3.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CRBU wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Rachel Haurwitz
Co-Founder13.1yrsUS$3.12m0.044%
$ 78.4k
Andrew Guggenhime
Independent Chairman3.6yrsUS$202.74k0%
$ 0
Jennifer Doudna
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Scott Braunstein
Independent Director3.4yrsUS$155.86k0%
$ 0
Katy Rezvani
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Martin Jinek
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Natalie Sacks
Independent Director6.5yrsUS$136.99k0%
$ 0
Cameron Turtle
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Ran Zheng
Independent Director3.2yrsUS$157.20k0%
$ 0
Nancy Whiting
Independent Director3.3yrsUS$140.62k0%
$ 0
Noopur Raje
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Ami Bhatt
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

3.5yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CRBU wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).